arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Monte Rosa Therapeutics, Inc.

GLUE

$15.89 ▲ +0.16 (+1.05%) at close

6 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Monte Rosa Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B

Dividend Yield —

Revenue Growth 63.5%

Op. Margin -43.8% ↗

ROIC -22.6% ↗

FCF / Share $-0.33 ↘

Trailing P/E —

Price / Book 4.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$123.67M

↑ +63.5% —

Net Income Profit after all expenses

$-38.63M

↑ +46.9% —

Operating Margin Operating profit as % of sales

-43.8%

↑ +59.1% 6th

FCF / Share Free cash flow per share

$-0.33

↓ -164.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	63.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+694%)	—	—	—	—	—
Net Income Growth YoY (%)	46.9% Excellent ↑ Excellent Improving Year-over-year change in net income	46.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-24.7% Weak ↑ Weak Improving Year-over-year change in net income	-46.7% Weak Weak Year-over-year change in net income	-106.1% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	N/M	N/M	45.2% Excellent Excellent Year-over-year change in free cash flow	19.3% Good Good Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	-43.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-392%)	-107.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-815%)	—	—	—	—
Effective Tax Rate (%) (%)	2.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-31.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-360%)	-96.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-901%)	—	—	—	—
FCF Margin (%) (%)	-22.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	50.3% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.71x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.46x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-22.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-80.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-45.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-12.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-18.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-56.7% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-16.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-210%)	-32.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-317%)	-75.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-603%)	-40.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-367%)	-21.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-242%)	-73.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-591%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-129.88M	$-224.25M	$-128.10M	$-54.91M	$-346.07M	$-41.70M

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$1.49	$1.02	$0.00	—	—	—
Free Cash Flow per Share (USD)	$-0.33	$0.51	$-1.22	$-2.23	$-2.76	—
Book Value per Share (USD)	$3.56	$3.62	$3.57	$5.50	$7.47	$28.91
Tangible Book Value per Share (USD)	$3.56	$3.62	$3.57	$5.50	$7.47	$28.91
Basic Weighted Avg Shares (shares)	83.07M	73.91M	51.40M	47.23M	25.00M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$328.97M	$220.49M	$189.62M	$250.32M	$332.03M	$14.32M
Total Equity (USD)	$233.06M	$222.94M	$179.25M	$271.41M	$347.51M	$48.73M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$123.67M	$75.62M	$0.00	—	—	—
Depreciation Expense (USD)	$8.36M	$8.12M	$6.22M	$3.75M	$2.13M	$537.00K
Net Income, GAAP (USD)	$-38.63M	$-72.70M	$-135.35M	$-108.50M	$-73.96M	$-35.88M
Operating Cash Flow (USD)	$-22.80M	$42.00M	$-43.80M	$-92.47M	$-59.36M	$-23.05M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 26 quarters

Monte Rosa Therapeutics, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare GLUE with peers